Watch: Sanofi to buy maker of hemophilia drug Bioverativ for $11.5b

Sanofi announced the purchase of Bioverativ, French maker of a drug treating hemophilia. The deal will close within three months and values Bioverativ at a 63% premium of their market price. Sanofi lost out on major deals in 2016 and hopes adding Bioverativ will boost its rare-disease business. Market competition is on the rise as new heavyweight firms gain traction.

Follow us on social media for the latest updates in B2B!

Latest

Bluedot’s Report Offers Restaurants Insight Into Consumer Spending Behaviors
September 23, 2022
Inflation and ongoing concerns of a recession are affecting consumer spending behaviors. And as always, the restaurant industry is a great place to take the temperature of what people are willing to Read more
Advancements in Bone Health Imaging with Dr. Ego Seeman
September 23, 2022
  CurveBeam AI Medical Director - Endocrinology Prof. Ego Seeman recently sat down with Vinti Singh, CurveBeam AI’s Marketing Director, to discuss the future of bone health imaging. Prof. Seeman is a Read more
OT and IT Edge Convergence and the Emergence of the Edge Marketplace
OT and IT Edge Convergence and the Emergence of the Edge Marketplace
September 23, 2022
To win the edge ecosystem game, it will take a village approach. Edge is no longer a linear value chain, going from step to step. An emerging circular value chain, with an open and extendable Read more